Top in hem/onc: Tecvayli approval; phase 2 data on prostate cancer therapy

Jansen Biotech said its drug Tecvayli received accelerated approval from the FDA after data showed that it benefited patients with relapsed or refractory multiple myeloma.

The indication of Tecvayli (teclistamab-cqyv) applies to adults who received at least four prior lines of therapy.

“The recent FDA approval of teclistamab is another incredible milestone in the immunotherapy approach to treating blood cancers,” Lee Greenberger, PhD, chief scientific officer of The Leukemia & Lymphoma Society, told Healio. “This new treatment option has the potential to improve the outcome for patients with the most serious forms of multiple myeloma.”

It was the top story in hematology/oncology last week.

Another top story was about a trial that showed a combination of intermittent hormone therapy and localized radiation therapy extended progression-free survival in patients with oligometastatic prostate cancer.

Read these and more top stories in hematology/oncology below:

FDA approves Tecvayli for advanced multiple myeloma

The FDA granted accelerated approval to teclistamab-cqyv for the treatment of certain patients with multiple myeloma. Read more.

Adding radiation to hormone therapy slows progression of oligometastatic prostate cancer

Adding localized radiation therapy to intermittent hormone therapy extended progression-free survival among men with oligometastatic prostate cancer, data from the randomized phase 2 EXTEND trial showed. Read more.

U.S. cancer death rates continue to drop as incidence remains stable

Cancer death rates declined broadly between 2015 and 2019 in the United States as overall incidence remained generally stable, according to the Annual Report to the Nation on the Status of Cancer. Read more.

Machine-learning approach using step counts predicts hospitalization during radiotherapy

An artificial intelligence model appeared to predict the likelihood of unplanned hospitalizations during chemoradiation therapy among a cohort of patients with various cancer types. Read more.

Hypofractionated radiation therapy ‘new standard of care’ for high-risk prostate cancer

Men with high-risk prostate cancer who received a shorter course of radiation therapy had similar survival and recurrence rates as those who received a longer, standard radiation therapy course, phase 3 trial results showed. Read more.